Katren OJSC 2017 Financial Report Out
Katren OJSC has published its annual marketing report on the results of the activities of the holding for 2017 on its website www.katrengroup.ru.
The document presents the key directions and key performance indicators for each subsidiary company included in Katren OJSC.
As Director General of Katren OJSC Vladimir Spiridonov notes in his address, “In the first half of the year, the Russian pharma market grew moderately, but the second half of the year was not so positive. Katren OJSC has a clear strategy how to move on, as well as the principles that help to implement this strategy. General tasks of the Katren OJSC in 2018 - strengthening leadership positions, improving business processes, optimizing costs and finding the best logistics solutions.”
The Group's revenue increased by 1,6 % compared to 2016, having amounted to RUB 243 billion, while the net profit reached RUB 1.4 billion.
Deloitte independent auditors have confirmed the 2017 financial statements.
The Katren OJSC 2016 Annual Marketing Report is published on the website of the holding in the “Investors / Annual Report” section and is also available under the link.
The annual marketing report is not an annual report in accordance with the requirements of Chapter 70 of the Bank of Russia Regulation No. 454-P dated 30 December 2014 “On Disclosure of Information by Issuers of Equity Securities.” The text of the Katren JSC Annual Report disclosed in accordance with the requirements of Chapter 70 of the Bank of Russia Regulation No. 454-P dated 30 December 2014 “On Disclosure of Information by Issuers of Equity Securities” will be published on the webpage http://e-disclosure.ruprovided to Katren JSC by the authorized agency Interfax on the website in the “Accounting” section after its approval by the General Meeting of Shareholders.
Katren Open Joint-Stock Company is a multinational group of companies running its operations in the distribution and retail segment of the pharmaceutical market. Katren OJSC owns companies in 4 countries.
Katren JSC, Russia
A parent holding company that is engaged in the distribution of medicines in all federal districts and constituent entities of the Russian Federation. Revenues in 2017 amounted to 210.2 billion rubles, which is 2.3% more than a year earlier. According to the international research agency IQVIA, Katren JSC tops the rating of commercial sales to end customers, and it ranks second in the total rating of pharmaceutical distributors for gross turnover and in the ranking of direct drug supplies.
VENTA.LTD LLC, Ukraine
According to the analytical system of market research PharmXplorer / Pharmstandard of Proxima Research, Venta LTD. is one of the three largest distributors in Ukraine in terms of the volume of medicines delivered to pharmacies. In 2017, the company's revenue growth was 12%.
MITY International LLP, Kazakhstan
One of the largest distributors on the Kazakhstani pharmaceutical market, occupying 9.3% of the commercial pharmaceutical market. In 2017, the revenue amounted to KZT25.8 billion. It was the first company in the pharmaceutical distribution sector of the Republic of Kazakhstan that has passed the ISO 9001: 2000 international certification and implemented the GDP standard. In 2017, the company EMITI International confirmed the certificate of GDP for the warehouse complex in Almaty.
Dominantapharm ALC, Republic of Belarus
Belarusian pharmaceutical distributor. In 2017, its increase in revenue amounted to 8%.
Melodiya Zdorovya Pharmacy Chain, Russia
The 2017 increase in turnover of this chain was 17%. The pharmacy chain incorporates 1082 pharmacies in 53 constituent entities of the Russian Federation, including franchises. RNC Pharma Analytical Company awarded Melodiya Zdorovya Pharmacy Chain with the 3th place in a comprehensive rating during the Russian pharmacy chains research.